摘要
We followed 188 euthyroidic persons undergoing treatment for multidrug resistant tuberculosis (MDR-TB) in the state of Karnataka, India to determine the incidence of hypothyroidism during anti-tuberculosis treatment. Overall, among MDR-TB patients with valid thyroid stimulating hormone (TSH) values, about 23% developed hypothyroidism (TSH value ≥10 mIU/ml) during anti-tuberculosis treatment;the majority (74%) occurring after 3 months of treatment. Among 133 patients who received a regimen that contained ethionamide, 42 (32%) developed hypothyroidism. Among 17 patients that received a regimen that contained para-aminosalicylate sodium, 6 (35%) developed hypothyroidism. Among 9 HIV positive patients on antiretroviral treatment, 4 (44%) developed hypothyroidism. These results differ from previously reported 4% incidence of hypothyroidism amongst patients who passively reported thyroidal symptoms during treatment, suggesting routine serologic monitoring of TSH throughout the course of treatment for MDR-TB is warranted.
We followed 188 euthyroidic persons undergoing treatment for multidrug resistant tuberculosis (MDR-TB) in the state of Karnataka, India to determine the incidence of hypothyroidism during anti-tuberculosis treatment. Overall, among MDR-TB patients with valid thyroid stimulating hormone (TSH) values, about 23% developed hypothyroidism (TSH value ≥10 mIU/ml) during anti-tuberculosis treatment;the majority (74%) occurring after 3 months of treatment. Among 133 patients who received a regimen that contained ethionamide, 42 (32%) developed hypothyroidism. Among 17 patients that received a regimen that contained para-aminosalicylate sodium, 6 (35%) developed hypothyroidism. Among 9 HIV positive patients on antiretroviral treatment, 4 (44%) developed hypothyroidism. These results differ from previously reported 4% incidence of hypothyroidism amongst patients who passively reported thyroidal symptoms during treatment, suggesting routine serologic monitoring of TSH throughout the course of treatment for MDR-TB is warranted.
作者
Somashekar Munivenkatappa
Singarajipura Anil
Balaji Naik
Tyson Volkmann
Karuna D. Sagili
Jayachamarajapura S. Akshatha
Shashidhar Buggi
Manchenahalli A. Sharada
Sudhendra Kulkarni
Vineet K. Chadha
Patrick K. Moonan
Somashekar Munivenkatappa;Singarajipura Anil;Balaji Naik;Tyson Volkmann;Karuna D. Sagili;Jayachamarajapura S. Akshatha;Shashidhar Buggi;Manchenahalli A. Sharada;Sudhendra Kulkarni;Vineet K. Chadha;Patrick K. Moonan(Drug Resistant Treatment Centre, Bengaluru, India;Sri Devarao Shivaram, Tuberculosis and Rajiv Gandhi Institute of Chest Diseases, Bengaluru, India;Revised National Tuberculosis Programme-State of Karnataka, Bengaluru, India;World Health Organization, India Country Office, New Delhi, India;U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA;International Union against Tuberculosis and Lung Disease (The Union), South-East Asia Regional Office, New Delhi, India;National Tuberculosis Institute, Bengaluru, India)
